CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 58,387 enrolled
Drug / intervention
Semaglutide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06914102
NCT06914102N/ACompleted
CompareCT.gov

Emulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims Data

Brigham and Women's Hospital·observational·Posted Apr 6, 2025·Updated Jan 30, 2026

In Brief

An observational study evaluating Semaglutide and Placebo for Diabetes Mellitus, Type 2 and HFpEF - Heart Failure With Preserved Ejection Fraction. Completed, enrolled 58,387 participants across 1 site.

Detailed Summary

Investigators are building an empirical evidence base for real-world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2, HFpEF - Heart Failure With Preserved Ejection Fraction
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20252026
First PostedApr 6, 2025
Enrollment StartJan 14, 2025
Primary CompletionJun 1, 2025
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 1.2 years ago

Interventions

Semaglutidedrug

New use of semaglutide dispensing claim is used as the exposure.

Placebodrug

New use of sitagliptin dispensing claim is used as the reference (active-comparator proxy for placebo).